← Back to patent-cliff list
Pirotinib Hydrochloride
Tier C — Watch / tradePirotinib Hydrochloride
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：HER4, EGFR, HER2
Indications (approved)：Breast cancer, Non-small cell lung cancer, Lung cancer, Solid tumour
Regional status
US
No progress
2015-04-07
EU
-
China
Phase II
2015-08-01
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Pirotinib Hydrochloride?
Approved indications include: Breast cancer, Non-small cell lung cancer, Lung cancer, Solid tumour.
When does the Pirotinib Hydrochloride patent expire?
No public expiry year is available for Pirotinib Hydrochloride yet; this page updates once verified.
How do I get a quote for Pirotinib Hydrochloride intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-11